SpyGlass Pharma secured $90 million in Series C financing to conduct multiple U.S. clinical trials of its drug delivery platform, according to a press release.
The financing was led by RA Capital Management along with existing investors New Enterprise Associates and Vensana Capital and new investors Samsara BioCapital and Vertex Ventures.
The IOL-mounted, controlled-release drug delivery platform is designed for multiple years of drug delivery to address unmet needs in glaucoma and other chronic ophthalmic diseases.
“We believe our approach represents a paradigm shift in the treatment of